Pharmaceutical interests versus AIDS in Africa

July 10, 2003

The appointment of Randall Tobias as the US Government's global AIDS co-ordinator is analysed in this week's editorial.

Tobias will head up a $15 billion programme to tackle AIDS in the African and Caribbean countries most devastated by the pandemic, although sceptics point out that his lack of knowledge about Africa and his pharmaceutical industry connections could weaken his appointment to this crucial role in global health. The editorial comments: 'Rapid appointment of a team behind him with proven African public-health and HIV experience would help him gain credibility in his new role, as would announcement of a detailed plan of how the Bush AIDS initiative will work with the Global Fund to Fight AIDS, Tuberculosis and Malaria. His connections with the pharmaceutical industry have led to concerns about whether Tobias is committed to providing access to low-cost generic AIDS drugs, or whether he will purchase patented versions so protecting the interests of US drug companies. Tobias needs quickly, and publicly, to support purchasing of low-cost generics to provide ammunition against those who charge that he is no more than a stooge of the drug industry. He could even go as far as to counter current US opposition to full implementation of the Doha Declaration of 2001.'

Recognising the significance of Tobias' appointment, the editorial concludes: 'Bush and Tobias together could, with the backing of Congress, change the nature of HIV/AIDS in Africa. If all Tobias' targets are met, which is likely only if the full US$15 billion is appropriated by Congress, then he will have proven himself a worthy Global AIDS Coordinator. Tobias' task then, surely, as befits his job title, will be to combat the emerging HIV pandemic in Asia.'


Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to